RBC Capital Increases United Therapeutics Corp. Price Target to $90.00 (UTHR)
Stock analysts at RBC Capital hoisted their price objective on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $80.00 to $90.00 in a report issued on Wednesday, Analyst Ratings Net reports. The firm currently has a “sector perform” rating on the stock. RBC Capital’s price objective would suggest a potential downside of 10.45% from the stock’s previous close.
In other United Therapeutics Corp. news, COO Roger Jeffs sold 10,000 shares of United Therapeutics Corp. stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $104.89, for a total value of $1,048,900.00. Following the completion of the sale, the chief operating officer now directly owns 897 shares of the company’s stock, valued at approximately $94,086. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
United Therapeutics Corp. (NASDAQ:UTHR) opened at 100.50 on Wednesday. United Therapeutics Corp. has a 52-week low of $56.85 and a 52-week high of $116.65. The stock’s 50-day moving average is $105.0 and its 200-day moving average is $90.44. The company has a market cap of $5.048 billion and a price-to-earnings ratio of 19.00.
United Therapeutics Corp. (NASDAQ:UTHR) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $2.88 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.51 by $1.37. The company had revenue of $289.02 million for the quarter, compared to the consensus estimate of $295.43 million. On average, analysts predict that United Therapeutics Corp. will post $5.41 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on UTHR. Analysts at Zacks upgraded shares of United Therapeutics Corp. from a “neutral” rating to an “outperform” rating in a research note on Friday, January 24th. They now have a $135.00 price target on the stock. Separately, analysts at Argus raised their price target on shares of United Therapeutics Corp. from $120.00 to $130.00 in a research note on Tuesday, December 31st. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Finally, analysts at Jefferies Group raised their price target on shares of United Therapeutics Corp. from $76.00 to $91.00 in a research note on Tuesday, December 24th. They now have a “hold” rating on the stock. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $92.64.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.